Medical Device

Roche Secures CE Mark for Elecsys IGRA TB Test, Delivering Automated Solution for Tuberculosis Infection Detection

CompanyDeals

InSilico Medicine Announces Strategic CNS Drug Discovery Collaboration with China Medical System, Eligible for RMB 1.2 Billion in Milestone Payments

CompanyDrug

TransThera Secures NMPA Approval for Phase 2 Trial of TT-00973 in Combination with Firmonertinib for EGFR-Mutant NSCLC

CompanyDeals

PegBio Partners with Rani Therapeutics on Oral Biologic Delivery Platform – Targeting Obesity and Metabolic Disease Candidates

CompanyDrug

Salubris Pharmaceuticals Secures NMPA IND Clearance for SAL0167 – Proprietary Cyclic Peptide Targeting Hyperlipidemia

CompanyDeals

Simcere Pharmaceuticals Forges Global Drug Discovery Alliance with Schrödinger – Combining Computational Platform with Therapeutic Expertise

CompanyDeals

Conba Pharmaceutical Secures Greater China Rights to Cebranopadol – First-in-Class Dual-Target Analgesic from Adneuris Therapeutics

CompanyDrug

Jacobio Pharma’s Incubator Secures NMPA IND Clearance for JAR-2203 Injection – Novel Therapy Targeting Hyperlipoproteinemia(a)

CompanyDrug

Haixi Pharma Launches Phase III Trial of C019199 – First-in-Class Multi-Targeted Immunomodulator for Refractory Osteosarcoma

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
CompanyDrug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

CompanyDrug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

CompanyDrug

Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial